← Back to Search

Telemedicine for Sickle Cell Anemia

N/A
Recruiting
Led By Seethal Jacob, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Caregivers must be 18 years or older, who have children between 0 to 21 years old with a diagnosis of Sickle Cell Disease and receive care at the Riley Hospital for Children Comprehensive Sickle Cell Disease clinic
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial will adapt and test two different types of telemedicine in order to improve care for children with sickle cell disease.

Who is the study for?
This trial is for caregivers over 18 with children (0-21 years) diagnosed with Sickle Cell Disease at Riley Hospital's clinic. Adolescents aged 16+ can also join. Participants must be willing to use telemedicine based on where they live, with specific distance criteria for different models.
What is being tested?
The study tests two telemedicine models: hub-and-spoke and direct-to-consumer, adapted for children with SCD. It aims to refine these models through stakeholder feedback and evaluate their effectiveness in improving care processes, satisfaction, patient outcomes, and healthcare usage.
What are the potential side effects?
Since the interventions involve types of telemedicine delivery rather than medications or medical procedures, traditional side effects are not applicable. However, there may be technical issues or challenges in communication that could affect the quality of care.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a caregiver, 18 or older, with a child (0-21) who has Sickle Cell Disease and is treated at Riley Hospital.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Caregiver feedback
Measuring adherence to appointment in sickle cell care.
Measuring adherence to lab draws in sickle cell care.
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Direct to ConsumerActive Control1 Intervention
Group II: Hub and SpokeActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
1,039 Previous Clinical Trials
1,218,998 Total Patients Enrolled
2 Trials studying Sickle Cell Anemia
395 Patients Enrolled for Sickle Cell Anemia
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,936 Previous Clinical Trials
47,792,593 Total Patients Enrolled
26 Trials studying Sickle Cell Anemia
2,458 Patients Enrolled for Sickle Cell Anemia
Seethal Jacob, MDPrincipal InvestigatorIndiana University

Media Library

Types of Telemedicine Delivery Models Clinical Trial Eligibility Overview. Trial Name: NCT05087303 — N/A
Sickle Cell Anemia Research Study Groups: Direct to Consumer, Hub and Spoke
Sickle Cell Anemia Clinical Trial 2023: Types of Telemedicine Delivery Models Highlights & Side Effects. Trial Name: NCT05087303 — N/A
Types of Telemedicine Delivery Models 2023 Treatment Timeline for Medical Study. Trial Name: NCT05087303 — N/A
~21 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top